3 Ways to Invest in the Nascent Psychedelics Industry
June 25th, 2020
Psychedelics, Top News
The psychedelics industry is projected to grow from about $2 billion in 2019 to nearly $7 billion by 2027, according to Data Bridge Market Research, representing a 16.3% compound annual growth rate. With ongoing clinical trials and support from the FDA, psychedelics could become a viable treatment option for a wide range of mental health disorders.
There are a growing number of companies in the psychedelics space and each one is taking a unique approach to the market. From wellness clinics to mushroom cultivation to pharmaceutical R&D, there are many ways for investors to participate in the industry’s potential growth. Many of these companies are diversifying or pivoting from the cannabis industry where they already have an operational footprint.
Let’s take a look at three ways to invest in the industry and publicly-traded companies that are well-positioned to capitalize on the market opportunities.
Investing in Clinics
Wellness clinics represent a near-term opportunity to generate revenue in the psychedelics space. For example, some companies are already providing ketamine therapies in the United States where the drug is used off-label for mood disorders. Psilocybin and other psychedelics have also been decriminalized in cities like Denver, Colorado, which could set the stage for wellness clinics to set up shop and help patients in a safe environment.
Empower Clinics Inc. (CSE: CBDT) (OTC: EPWCF) owns and operates a network of CBD-focused clinics in Oregon and Arizona, and provides telemedicine services nationwide with more than 165,000 patients. In addition, the company has a 5,000 sq. ft. production facility in Oregon that manufactures premium health and wellness products for its clinics—including its Sollievo CBD product line.
The company recently launched a psilocybin subsidiary to explore the possibility of expanding into psychedelics. With an existing clinic footprint and manufacturing facility, the company could be in a unique position to expand into psychedelics in the United States.
Investing in Production
Psychedelics face the same problems as cannabinoids when it comes to scaling up production. Since they are plant-based extracts, there is a cultivation and extraction process involved that can be both costly and time consuming. Some companies are perfecting ways to shortcut the process and create purer compounds that could make cannabinoids and psychedelics more potent and cost effective.
CB Therapeutics Inc. is a venture-stage company that has developed a proprietary cellular agriculture platform designed to efficiently research and produce therapeutic compounds. While its initial focus has been on producing cannabinoids for nutraceuticals, the company’s 7,000 sq. ft. fully-licensed commercial batch facility could potentially expand into the cultivation of tryptamines, such as psilocybin and DMT for accredited clinical trials.
The company could become a key supplier of these psychedelic compounds to researchers during the early stages of the industry before moving on to become a producer for commercial companies once the compounds are approved.
Investing in Pharmaceuticals
The pharmaceutical industry provides high-risk, high-reward opportunities for investors. While the clinical trial process is costly and time-consuming, approved drugs enjoy a period of market exclusivity where companies enjoy high margins and barriers to entry. The promise of psychedelics in treating mental health disorders could create an entirely new generation of drugs that effectively address several large multi-billion dollar markets.
Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) is a life sciences company that’s focused on infectious diseases and rare disorders. Unlike other pharma companies, it prioritizes development efforts that take advantage of FDA incentives, such as Orphan Drug or Fast Track designations. The company’s current operations are focused on COVID-19 treatment possibilities as well as the burgeoning psychedelics market.
The company’s recent acquisition of Psilocin Pharma Corp. underscores its commitment to the research and development of psychedelic therapies and investors may want to keep an eye on its clinical programs given its unique focus on FDA incentives.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.